Literature DB >> 29065724

Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors.

Marie Liebig1, Alireza Hassanzada1, Malte Kämmerling1, Berit Genz1,2, Brigitte Vollmar1, Kerstin Abshagen1.   

Abstract

Non-alcoholic fatty liver disease is closely associated with metabolic syndrome and comprises a pathological spectrum of liver disease ranging from steatosis to steatohepatitis and can progress to fibrosis/cirrhosis and hepatocellular carcinoma. In 2013, a mouse model was described that mimics non-alcoholic fatty liver disease progression from steatohepatitis to tumors in a short time span and with high incidence. As microcirculatory disturbances play a crucial role in liver disease, the suitability of the steatosis-inflammation-tumor model for microcirculatory studies was assessed. Herein, we present a comprehensive view on morphological, microvascular, cellular, and functional aspects of non-alcoholic fatty liver disease progression in the steatosis-inflammation-tumor model using intravital microscopy, biochemical, and histological techniques. Mice develop steatohepatitis, mild fibrosis, and liver tumors at ages of 6, 12, and 20 weeks, respectively. Non-alcoholic fatty liver disease progression was accompanied by several general aspects of disease severity like increasing liver/body weight index, non-alcoholic fatty liver disease activity score, and hepatocellular apoptosis. Intravital microscopic analysis revealed significant changes in hepatic microcirculation with increasing structural alterations, elevated leukocyte adherence, and impaired nutritive perfusion. Non-alcoholic fatty liver disease was further characterized by a lower sinusoidal density with a striking rise at 20 weeks. The characteristic microcirculatory changes make the model a convenient tool for analysis of microcirculation during progression from steatosis to liver tumor. Impact statement Significant alterations of microcirculation contribute to progression of NAFLD, a chronic liver disease with increasing medical and socio-economic impact. Characterization of microcirculation in a NAFLD model reflecting all relevant stages of disease progression was still missing. Thus, we evaluated microcirculatory and cellular changes in a steatosis-inflammation-tumor model using in vivo microscopy. Analyses revealed increasing structural alterations, elevated leukocyte-endothelial interaction, and impaired nutritive perfusion. Thus, this model is suitable for further studies investigating therapeutic approaches targeting these progressive microcirculatory disturbances.

Entities:  

Keywords:  Non-alcoholic fatty liver disease; hepatic microcirculation; hepatocellular carcinoma; intravital microscopy; steatohepatitis

Mesh:

Year:  2017        PMID: 29065724      PMCID: PMC5788156          DOI: 10.1177/1535370217738730

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  53 in total

1.  Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice.

Authors:  Virginia Maina; Salvatore Sutti; Irene Locatelli; Matteo Vidali; Cristina Mombello; Cristina Bozzola; Emanuele Albano
Journal:  Clin Sci (Lond)       Date:  2012-06       Impact factor: 6.124

2.  M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease.

Authors:  Jinghong Wan; Merieme Benkdane; Fatima Teixeira-Clerc; Stéphanie Bonnafous; Alexandre Louvet; Fouad Lafdil; Françoise Pecker; Albert Tran; Philippe Gual; Ariane Mallat; Sophie Lotersztajn; Catherine Pavoine
Journal:  Hepatology       Date:  2013-11-20       Impact factor: 17.425

3.  The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.

Authors:  Austin L Spitzer; Oliver B Lao; André A S Dick; Ramasamy Bakthavatsalam; Jeffrey B Halldorson; Matthew M Yeh; Melissa P Upton; Jorge D Reyes; James D Perkins
Journal:  Liver Transpl       Date:  2010-07       Impact factor: 5.799

4.  Type of steatosis influences microcirculation and fibrogenesis in different rat strains.

Authors:  Stephan Rosenstengel; Sandra Stoeppeler; Ralf Bahde; Hans-Ullrich Spiegel; Daniel Palmes
Journal:  J Invest Surg       Date:  2011       Impact factor: 2.533

5.  In vivo demonstration of impaired microcirculation in steatotic human liver grafts.

Authors:  A M Seifalian; V Chidambaram; K Rolles; B R Davidson
Journal:  Liver Transpl Surg       Date:  1998-01

Review 6.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

7.  Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice.

Authors:  Robert S McCuskey; Yoshiya Ito; Graham R Robertson; Margaret K McCuskey; Michael Perry; Geoffrey C Farrell
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

8.  Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.

Authors:  Yoko Takaki; Yoshimasa Saito; Azusa Takasugi; Kohta Toshimitsu; Shoji Yamada; Toshihide Muramatsu; Masaki Kimura; Kazuo Sugiyama; Hiromu Suzuki; Eri Arai; Hidenori Ojima; Yae Kanai; Hidetsugu Saito
Journal:  Cancer Sci       Date:  2014-09-25       Impact factor: 6.716

9.  L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.

Authors:  Hisashi Ishikawa; Akinobu Takaki; Ryuichiro Tsuzaki; Tetsuya Yasunaka; Kazuko Koike; Yasuyuki Shimomura; Hiroyuki Seki; Hiroshi Matsushita; Yasuhiro Miyake; Fusao Ikeda; Hidenori Shiraha; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

Review 10.  Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse.

Authors:  Jesse D Riordan; Joseph H Nadeau
Journal:  Mamm Genome       Date:  2014-05-07       Impact factor: 2.957

View more
  4 in total

1.  Limited potential of resolvin D1 in treatment of cholestatic liver fibrosis.

Authors:  Kerstin Abshagen; Alexander Hartmann; Laura Grüner; Marie Liebig; Brigitte Vollmar
Journal:  Hepatobiliary Surg Nutr       Date:  2020-10       Impact factor: 7.293

2.  The effect of different weight loss strategies to treat non-alcoholic fatty liver disease focusing on fibroblast growth factor 21.

Authors:  Nicole Power Guerra; Katharina Leyens; Luisa Müller; David Brauer; Deborah Janowitz; Samin Schlick; Kristin Pilz; Hans J Grabe; Brigitte Vollmar; Angela Kuhla
Journal:  Front Nutr       Date:  2022-08-10

3.  Endogenously increased n-3 PUFA levels in fat-1 transgenic mice do not protect from non-alcoholic steatohepatitis.

Authors:  Marie Liebig; Dirk Dannenberger; Brigitte Vollmar; Kerstin Abshagen
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

4.  n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model.

Authors:  Marie Liebig; Dirk Dannenberger; Brigitte Vollmar; Kerstin Abshagen
Journal:  Ther Adv Chronic Dis       Date:  2019-09-05       Impact factor: 5.091

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.